LGND Q3 2020 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+68.7% YoY

Gross Profit

$35M84.8% margin

Operating Income

$4M9.0% margin

Net Income

-$7M-16.0% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+1.0%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$11M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$550M

Stockholders' Equity

$698M

Cash & Equivalents

$457M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$25M	+68.7%
Gross Profit	$35M	$22M	+63.9%
Operating Income	$4M	-$5M	+172.6%
Net Income	-$7M	-$15M	+56.1%

Revenue Segments

Material Sales, Captisol

$23M39%

Contract Revenue

$9M16%

Royalty

$9M15%

Contract Revenue, Service

$7M12%

Kyprolis

$7M11%

Evomela

$2M3%

License Fees, Milestones, and Product, Other, Product, Other

$995,0002%

Milestone

$960,0002%

Royalty, Other

$280,0000%

License Fees

$158,0000%